# Why Pharma Is Taking Cannabis Seriously – The Dales Report > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/why-pharma-is-taking-cannabis-seriously-the-dales-report/ > **Published:** 2026-06-13T12:05:45-04:00 | **Last Modified / Clinically Audited:** 2026-09-08T20:23:42-04:00 > **Clinical Summary:** Pharma's three-tier cannabis model signals shift toward clinical standardization, dosing consistency, and FDA-grade oversight—what clinicians need to know. --- ✦ New CED Clinical Relevance #35 Clinical Context Background information relevant to the evolving [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) landscape. ResearchPolicyIndustryPainMental HealthCBDTHC Clinical Summary # Clinical Summary The pharmaceutical industry’s increasing engagement with cannabis reflects growing recognition of its therapeutic potential and evolving regulatory frameworks that create opportunities for standardized, evidence-based cannabinoid products. Pharmaceutical companies are positioning themselves across a three-tiered market structure encompassing craft adult-use products, medical cannabis dispensaries, and pharmaceutical-grade formulations, signaling that cannabis is transitioning from an unregulated commodity to a legitimately developed therapeutic category. This shift has implications for clinicians as it may lead to improved product standardization, consistent dosing, quality control, and [clinical research](https://cedclinic.com/cannabis-based-therapies-smoking-cessation/) supporting cannabinoid therapies, similar to the path taken by other plant-derived pharmaceuticals like digoxin or artemisinin. As major pharmaceutical players invest in [cannabis research](https://cedclinic.com/pediatric-cannabis-certification-care-children/) and development, patients may eventually gain access to regulated, prescription-grade cannabinoid medications with known pharmacokinetics and safety profiles comparable to conventional pharmaceuticals. For clinicians, the pharmaceutical industry’s involvement signals that cannabis-based therapies are moving toward the evidence and regulatory standards necessary to integrate cannabinoids into mainstream clinical practice. Dr. Caplan’s Take “The pharmaceutical industry’s shift toward [cannabinoid research](https://cedclinic.com/cannabinoids-in-reward-processing-pain-perception/) represents a validation of what we’ve observed clinically for years, but it also means we need to be vigilant about ensuring that whole-plant medicine and isolated compounds serve different patient needs rather than one replacing the other.” Clinical Perspective 💊 The pharmaceutical industry’s growing engagement with cannabis reflects both genuine therapeutic potential and significant commercial opportunity, making it important for clinicians to understand the distinction between evidence-based [cannabinoid medicine](https://cedclinic.com/cannabinoids-prostate-cancer-anti-tumor-drugs/) and market-driven product development. While legitimate pharmaceutical research into cannabinoids for specific indications (such as chemotherapy-induced nausea or certain seizure disorders) continues to advance, the industry’s enthusiasm may outpace the current evidence base for many proposed uses, and clinicians should remain cautious about extrapolating from positive early-stage research to clinical recommendations. The heterogeneity of cannabis products, variable cannabinoid and terpene profiles, and limited standardization present ongoing challenges that differ fundamentally from traditional pharmaceutical development, yet these complexities are often underappreciated in commercial messaging. As pharmaceutical companies move toward cannabinoid-based therapeutics, clinicians should prioritize evidence from rigorous clinical trials while maintaining healthy skepticism about off-label cannabis 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-related-research/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Why%20Pharma%20Is%20Taking%20Cannabis%20Seriously%20-%20The%20Dales%20Report%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D58976)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D58976)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Why%20Pharma%20Is%20Taking%20Cannabis%20Seriously%20-%20The%20Dales%20Report%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2F%3Fp%3D58976)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) 📰 Source: [https://thedalesreport.com/cannabis/why-pharma-is-taking-cannabis-seriously/](https://thedalesreport.com/cannabis/why-pharma-is-taking-cannabis-seriously/) Further Reading CED Clinic Blog[Why Cannabis Works](https://cedclinic.com/why-cannabis-works/) Evidence Watch[Cannabis and Heart Health](https://cedclinic.com/cannabis-cardiovascular-health-study/) CED Clinic Blog[Cannabis for Sleep](https://cedclinic.com/cannabis-for-sleep/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).